The inclusion of ondansetron helps improve tolerability for many patients starting Semaglutide therapy by addressing one of its most common and disruptive side effects
Semaglutide is not listed as prohibited by WADA at this time, but rules change, and ethical questions about weight management in competitive sport exist separately from formal prohibition
Semaglutide is commonly used in the management of type 2 diabetes and obesity
For instance, GLP-1 receptor agonists like semaglutide slow down how quickly your stomach empties and influence hormones that control appetite
Wegovys official safety information lists nausea, diarrhea, vomiting, constipation, stomach pain, bloating, belching, gas, and heartburn among common possible side effects, which is why this post stays practical and careful